There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols?

There is a Cut Off Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome? A Randomized Controlled Trial in Fixed Versus Flexible Gonadotropin-releasing Hormone Antagonist Protocols.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02328924

Enrollment

213

Registered

2014-12-31

Start date

2012-05-31

Completion date

2013-09-30

Last updated

2014-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility

Brief summary

This study, prospective randomized controlled trial, tried to identify a cut off value of luteinizing hormone predictive of in vitro fertilization outcome in a fixed or flexible gonadotropin-releasing hormone antagonist protocols. 202 norma-ovulatory women \< 39 years were randomized to fixed or flexible group in GnRH antagonist protocols The follicular phase profile of luteinizing hormone, estradiol and progesterone in the two study groups was measured. Total number of retrieved oocytes, implantation and pregnancy rate were recorded. .

Interventions

OTHERLH value

analyzed LH value in the the arms of the study, fixed and flexible protocols

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

35 Years to 39 Years

Healthy volunteers

Yes

Inclusion criteria

* 1\) age \<39 years; (2) normal menstrual cycle (range of 26-32 days); (3) baseline follicle stimulating hormone levels \< 12 IU/ml; (4) body mass index (BMI) between 18-30 Kg/m2; (5) no oral contraceptive pills taken in the last year

Exclusion criteria

* polycystic ovaries, age \>39 years

Design outcomes

Primary

Measure	Time frame
number of mature oocytes recruited after IVF with antagonist protocol	partecipant will be followed for the duration of the cycle of IVF and for the following three months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026